Help
RSS
API
Feed
Maltego
Contact
Domain > en.delovabio.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2026-02-22
47.251.60.72
(
ClassC
)
Port 80
HTTP/1.1 200 OKServer: nginxDate: Sun, 22 Feb 2026 11:03:37 GMTContent-Type: text/html; charsetutf-8Transfer-Encoding: chunkedConnection: keep-aliveVary: Accept-EncodingCache-Control: no-cache, must-revalidateStrict-Transport-Security: max-age31536000 !DOCTYPE html>html langen>head>meta charsetUTF-8>meta http-equivX-UA-Compatible contentIEedge>meta nameviewport contentwidthdevice-width, initial-scale1.0>title>delovabio/title>meta namekeywords content />meta namedescription content />link relicon href/favicon.ico>link relstylesheet href/ydyweb_static/css/animate.css>link relstylesheet href/ydyweb_static/css/web.css>script src/ydyweb_static/js/jquery-1.11.3.min.js>/script>script src/ydyweb_static/js/wow.min.js>/script>script src/ydyweb_static/js/wesen.js>/script>script src/ydyweb_static/js/web.js>/script>meta nameformat-detection contenttelephoneno />/head>body data-genre>!-- header -->header classheader> div classw1440> !-- logo --> h1 classheader-logo> a href/> img srccommon/assets/logo.svg alt> img src/ydyweb_static/picture/logo3.svg alt> /a> /h1> !-- menu --> div classheader-menu data-toggleoffcanvas data-target#offcanvasMenu > span>/span> span>/span> /div> /div>/header>!-- offcanvasMenu -->div classmodal nav-menu idoffcanvasMenu> div classmodal-close data-toggleoffcanvas data-target#offcanvasMenu > img src/ydyweb_static/picture/close.svg alt> /div> jtbc-pitchon pitchonligenre> ul> li genre>a href./>Home/a>/li> li genreabout>a href/about/>Company Profile/a>/li> li genrepain>a href/pain/>Pain/a>/li> li genreplatform>a href/platform/>Technology Platform/a>/li> li genrepipeline>a href/pipeline/>Product Pipeline/a>/li> li genrenews>a href/news/>News/a>/li> li genrejob>a href/job/>Job Application/a>/li> li>a hrefhttps://www.delovabio.com/ classcur>CN/a>a href/>EN/a>/li> /ul>/jtbc-pitchon>/div> link relstylesheet href/ydyweb_static/css/swiper.min.css>!-- home part1 -->div classhome-part1 stylebackground-image: url(/common/upload/universal/fragment/2024/03/18/071612ab.jpg);> div classw1440> !-- txt --> div classtxt> p classwow fadeInUp data-wow-duration2.5s>Focus on the development of new drugs in the field of pain./p> p classwow fadeInUp data-wow-duration2.5s>Provide non-opioid analgesics to satisfy unmet medical needs./p> a href/about/ classmore wow fadeInUp data-wow-duration2.5s> About Us /a> /div> /div>/div>!-- home concept -->div idhomeConcept classhome-concept stylebackground-image: url( /common/upload/universal/fragment/2024/03/16/153107vz.jpg> div classw1440> div classweb-title wow fadeInUp data-wow-duration2.5s>/div> div classweb-title2 wow fadeInUp data-wow-duration2.5s>R&D Concept/div> !-- txt --> div classtxt wow fadeInUp data-wow-duration2.5s> p>The Company was established based on the unmet medical needs and driven by technological innovation. The Company focuses on the development of high-barrier innovative technology platforms such as long-acting injection technology, topical formulation transdermal technology, nano-delivery carrier technology, prodrug modification, and solubility enhancement technology for insoluble drugs. The Company puts a lot of emphasis on patent protection throughout the full life cycle of drug development./p>p> /p>p>The Company emphasizes a global market layout and maximize the value of the projects by launching clinical studies and product registration simultaneously in China and US. The sales scale of the series of products can be up to tens of billions RMB after they are on the market. The Company's product pipeline covers two application pathways, i.e., 505(b)(1) and 505(b)(2), with a total of nearly 10 new drug products. The Company has held a pre-NDA meeting with US FDA for its first project, QP001, and has reached several agreements./p> /div> !-- more --> a href/about/#aboutConcept classmore wow fadeInUp data-wow-duration2.5s> i>Learn more/i> span>img src/ydyweb_static/picture/more.svg alt>/span> /a> !-- star --> div classstar1 parallax-factor0.3>img src/ydyweb_static/picture/star1.svg>/div> /div>/div>!-- home professional -->div idhomeProfessional classhome-professional> div classw1440> div classweb-title wow fadeInUp data-wow-duration2.5s>/div> div classweb-title2 wow fadeInUp data-wow-duration2.5s>Therapeutic Areas/div> !-- box --> div classbox wow fadeInUp data-wow-duration2.5s> div classpic>img src/common/upload/index/area/2024/03/23/1145142m.jpg alt>/div> div classwords> div classtitle>Pain/div> div classtxt>Pain is a complex physiological and psy-chological activity, and is one of the com-monest clinical symptoms. It is gaining more and more attention as the 5th vital sign after blood pressure, respiration, pulse, and body temperature. In 2020, the International Association for the Study of Pain (IASP) revised the definition of pain to an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage./div> div> a href/pain/ classmore> i>Learn more/i> span>img src/ydyweb_static/picture/more.svg alt>/span> /a> /div> /div> /div> !-- star --> div classstar2 parallax-factor0.3>img src/ydyweb_static/picture/star2.svg>/div> /div>/div>!-- home products -->div idhomeProducts classhome-products> div classbox> div classw1440> div classweb-title wow fadeInUp data-wow-duration2.5s>/div> div classweb-title2 wow fadeInUp data-wow-duration2.5s>Platform/div> !-- star --> div classstar3 parallax-factor0.3>img src/ydyweb_static/picture/star3.svg>/div> /div> /div> div classproductSwiper> div classswiper-container> div classswiper-wrapper> div classswiper-slide> div classproduct-item1 stylebackground-image: url(/common/upload/index/platform/2024/03/23/131846we.jpg);> div classsub-title>XisGelspan>®/span>/div> div classtitle>Sustained-release Gel Platform/div> div classtxt>XisGelspan>®/span>technology is suitable for improving the local duration of action of short half-life drugs.../div> a href/platform/#platformProduct1 classmore> svg width19 height19 viewBox0 0 19 19 fillnone xmlnshttp://www.w3.org/2000/svg> path dM3.89795 14.9456L15.0938 3.7497 stroke#103149 stroke-width0.791667/> path dM9.44092 3.86206H15.0388V9.45999 stroke#103149 stroke-width0.791667/> /svg> /a> /div> /div>div classswiper-slide> div classproduct-item1 stylebackground-image: url(/common/upload/index/platform/2024/03/23/1318492i.jpg);> div classsub-title>ETPFspan>®/span>/div> div classtitle>Topical Skin Preparation Platform/div> div classtxt>ETPFspan>®/span>technology is suitable for im-proving the bioavailability and ease of use of topical.../div> a href/platform/#platformProduct2 classmore> svg width19 height19 viewBox0 0 19 19 fillnone xmlnshttp://www.w3.org/2000/svg> path dM3.89795 14.9456L15.0938 3.7497 stroke#103149 stroke-width0.791667/> path dM9.44092 3.86206H15.0388V9.45999 stroke#103149 stroke-width0.791667/> /svg> /a> /div> /div> /div> /div> /div>/div>!-- home data -->div idhomeData classhome-data> div classw1440> !-- intro --> div classintro> div classintro-left wow fadeInLeft data-wow-duration2.5s> div classweb-title>/div> div classweb-title2>Pipeline/div> /div> div classintro-right wow fadeInRight data-wow-duration2.5s> div classtxt> p>Delova Biotech focuses on the unmet medical needs in the field of pain in both China and U.S. The Company has laid out nearly 10 new non-opioid analgesics, which have sequen-tially entered the clinical development stage. The Company has also applied for nearly 20 key patents./p> /div> a href/pipeline/ classmore> Learn more span>img src/ydyweb_static/picture/more2.svg alt>/span> /a> /div> /div> !-- data --> div classdata> div classbox> div classdl> div classdt>Laid out nearly 10 new non-opioid analgesics/div> div classdd>span classwow fadeIn data-wow-duration2.5s>10/span>款/div> /div> div classdl> div classdt>US pre-NDA Submitted/div> div classdd>span classwow fadeIn data-wow-duration2.5s>01/span>项/div> /div> div classdl> div classdt>Domestic Clinical/div> div classdd>span classwow fadeIn data-wow-duration2.5s>01/span>项/div> /div> /div> /div> !-- star --> div classstar4 parallax-factor0.3>img src/ydyweb_static/picture/star4.svg>/div> /div>/div>div classjob-new> div classjob-newRightTop>/div> div classjob-new-right wow fadeInLeft data-wow-duration2.5s stylevisibility: visible; animation-duration: 2.5s; animation-name: fadeInLeft;> !--div classweb-title>/div>--> div classweb-title2>Career opportunities/div> div classjob-border>/div> div classjob-new-content wow fadeInRight data-wow-duration2.5s stylevisibility: visible; animation-duration: 2.5s; animation-name: fadeInRight;> p>We respect the spirit of science, encourage free exploration, focus onclinical needs, and are committed to bringing healthier, more comfortable, and hiqher-level lives to pain patients./p>p>We provide challenging, fulfilling, and fast-growing career opportunitiesand welcome like-minded partners to join!/p> /div> a href/job/ classmore job-new-more> Learn more span>img src/ydyweb_static/picture/more2.svg>/span> /a> /div> div classjob-new-container> div classjob-new-container-title>公司和你一起高速发展/div> div classjob-new-container-title2>招聘职位/div> ul> li>a href/job/#job>临床监查员CRA/a>/li>li>a href/job/#job>临床医学经理/a>/li>li>a href/job/#job>药物分析研究员/a>/li>li>a href/job/#job>药物制剂研究员/a>/li>li>a href/job/#job>医学撰写/a>/li> /ul> /div> /div> !-- modify -->!-- home new-->div idhomeNew classhome-new> div classw1440> div classhome-new-left wow fadeInLeft data-wow-duration2.5s> div classweb-title>/div> div classweb-title2>News/div> a href/news/ classmore> Learn more span>img src/ydyweb_static/picture/more2.svg>/span> /a> /div> div classhome-new-right wow fadeInRight data-wow-duration2.5s> ul> li> div classimg onclickwindow.open(https://mp.weixin.qq.com/s?__bizMzI5MDU1MDU1NQ&mid2247483886&idx1&sn7503cc5b9ad497d3d39712f87a78ec79&chksmec1f679adb68ee8ce2bf758f6a7c46692ef8e3edbf56f7fe7404db830c00fa92226cc57e371e#rd) >img src/common/upload/news/2024/03/16/1548560r.png alt>/div> div classwords> div classtitle onclickwindow.open(https://mp.weixin.qq.com/s?__bizMzI5MDU1MDU1NQ&mid2247483886&idx1&sn7503cc5b9ad497d3d39712f87a78ec79&chksmec1f679adb68ee8ce2bf758f6a7c46692ef8e3edbf56f7fe7404db830c00fa92226cc57e371e#rd) > “无痛之路”上的冲刺跑者/div> div classmemo>2022年，生物医药行业政策调整加码，疫情笼罩、资本寒冬之下行业加速洗牌重塑，部分药企传出寒气，然而正是在这样的行业重塑过程中，真正的创新才能突出重围，牵手资本助力，迎来明亮曙光。/div> /div> div classnews-info modal idoffcanvasNew9> div classmodal-close data-toggleoffcanvas data-target#offcanvasNew9> img src/ydyweb_static/picture/close2.svg alt> /div> div classtime>2023-01-20/div> div classcaption>“无痛之路”上的冲刺跑者/div> div classcontent> div classscroll scrollCss> div classedit> /div> /div> /div> /div> /li> li> div classimg data-toggleoffcanvas data-target#offcanvasNew6 data-id6>img src/common/upload/news/2024/03/16/095340o0.jpg alt>/div> div classwords> div classtitle data-toggleoffcanvas data-target#offcanvasNew6 data-id6> 南京清普生物QP001 | CDE正式受理首款长效镇痛新药NDA/div> div classmemo>北京时间2023年09月07日，南京清普生物收到国家药品监督管理局药品审评中心（CDE）关于QP001注射液新药上市申请（NDA）的受理通知书。/div> /div> div classnews-info modal idoffcanvasNew6> div classmodal-close data-toggleoffcanvas data-target#offcanvasNew6> img src/ydyweb_static/picture/close2.svg alt> /div> div classtime>2023-09-08/div> div classcaption>南京清普生物QP001 | CDE正式受理首款长效镇痛新药NDA/div> div classcontent> div classscroll scrollCss> div classedit>p> 北京时间2023年09月07日，strong>南京清普生物收到国家药品监督管理局药品审评中心（CDE）关于QP001注射液新药上市申请（NDA）的受理通知书/strong>。两个月前，南京清普生物已收到FDA关于QP001项目NDA的正式受理函，NDA号为217593。QP001有望成为国内首款中美同步获批上市的镇痛新药。/p>p> /p>p>【关于QP001】/p>p> QP001注射液是清普生物系列非阿片类镇痛新药管线的首款产品，中美双报，可用于治疗各类急性疼痛，尤其适用于术后疼痛，相比现有同类药物在镇痛强度、安全性和镇痛维持时间上均有显著优势。QP001项目基于清普自主知识产权的难溶药物增溶技术平台（SimSolsup>TM/sup>）开发。/p>p> 此前，南京清普生物已收到FDA关于QP001项目的“Application Fee Waivers”（注册费用减免）确认函。根据美国《联邦食品、药品和化妆品法案》（FD&C Act）第736(d)(1)(C)章，strong>南京清普生物可享受QP001项目NDA注册费用部分减免的优惠，成为国内极少数获得FDA“Application Fee Waivers”（注册费用减免）的生物医药公司之一/strong>。/p>p> /p>p> 本次国内NDA基于两项确证性III期临床试验，共50余家临床研究中心参与，用时9个月不到完成全部受试者入组。两项III期临床结果优异，各主要终点和次要终点均达到统计学差异，确证了QP001注射液在24h内可保持强效镇痛，镇痛强度和安全性均优于同类药物。/p>p> /p>p> QP001项目在近2年时间里接连不断地超预期攻克国内外研发和注册里程碑，完成了多项“strong>国内第一/strong>”的壮举，彰显了公司研发团队独一无二的“清普速度”和“清普质量”。/p>p>img src/common/upload/news/2024/03/16/095419xm.jpg>/p>p> /p>p>【关于术后疼痛】/p>p> 术后疼痛是临床上最常见的急性疼痛，通常持续3～7天，创伤大的胸科和关节置换术可持续数周，日间手术离院后需1-2天镇痛。根据《中国卫生健康统计年鉴》报告，2021年我国住院手术达到8103万台，2017-2022年复合增长率（CAGR）约10%，其中约92.6%患者在手术后出现疼痛，48.7%患者术后会经历中度至重度疼痛。/p>p> 目前我国仍存在术后镇痛不足的现象，strong>我国三级甲等医院有效镇痛率也仅约30%/strong>，临床缺少强效且长效的非阿片类镇痛药。术后镇痛不足可使患者处于伤害性应激状态，影响术后恢复，导致住院时间延长，引起睡眠障碍，影响心理情绪和交感神经兴奋，增加心脏负荷影响呼吸功能，使得胃肠蠕动减少和功能恢复延迟等，并有演变为慢性疼痛的风险。/p>p> strong>国内外指南共识推荐NSAIDs类药物作为术后多模式镇痛的基础用药/strong>，按时给药，并推荐使用长效NSAIDs药物（尤其是日间手术），术前即给予COX-2选择性抑制剂预防性镇痛，进而降低术后阿片类镇痛药的用量，避免阿片类药物成瘾性、呼吸抑制、恶心呕吐、便秘等一系列不良反应。/p>p> /p>p> img src/common/upload/news/2024/03/16/095419a0.jpg>/p> /div> /div> /div> /div> /li> li> div classimg data-toggleoffcanvas data-target#offcanvasNew4 data-id4>img src/common/upload/news/2024/03/16/095022ui.jpg alt>/div> div classwords> div classtitle data-toggleoffcanvas data-target#offcanvasNew4 data-id4> 秋游 | 成群结队 快乐加倍/div> div classmemo>2023年清普生物秋游小记/div> /div> div classnews-info modal idoffcanvasNew4> div classmodal-close data-toggleoffcanvas data-target#offcanvasNew4> img src/ydyweb_static/picture/close2.svg alt> /div> div classtime>2023-09-28/div> div classcaption>秋游 | 成群结队 快乐加倍/div> div classcontent> div classscroll scrollCss> div classedit>p>早秋天气晴好，微风阵阵。为了感谢大家一直以来的付出与努力，公司在9月24日和25日于安吉组织了主题为“To the beyond 走向超越”的秋游活动，让大家从繁忙的工作中得到抽离，亲近自然、舒缓心情。/p>p>strong>浙北大峡谷·心跳在云霄/strong>/p>p>在首日行程中的浙北大峡谷不仅可以体验爬山观水的乐趣，还可以在“云幻之城”高山游乐区进行自我勇气值拉满的高空项目挑战，步步惊心桥、空中自行车、悬崖秋千等多个高空项目激发了小伙伴们挑战自我的勇气，展示真我。/p>p> img styledisplay: block; margin-left: auto; margin-right: auto; src/common/upload/news/2024/03/16/095041rm.jpg width500>/p>p> /p>p> /p>p>strong>烧烤与篝火·吹动少年的心/strong>/p>p>日落时分，伴随着烧烤炉中的炭火闪烁，大家开始了2023年秋天的第一场烧烤，刷油、翻面，生疏的动作并不影响烧烤的美味，每出炉一盘肉，就被一扫而空。举杯、摆拍，当下就是最放松且自由的时刻跳动的篝火将轻松愉悦的氛围推向高潮。/p>p> /p>p> /p>p> /p>p>img styledisplay: block; margin-left: auto; margin-right: auto; src/common/upload/news/2024/03/16/095034wc.jpg width500>/p>p>strong>竹博园·森呼吸/strong>/p>p>行程中的第二日是竹博园定向活动，分成三组的小伙伴们，组内齐心协力，组外不甘示弱。/p>p> /p>p> img styledisplay: block; margin-left: auto; margin-right: auto; src/common/upload/news/2024/03/16/095034pp.jpg width500>/p>p> /p>p>此次秋游，让大家亲近自然，享受美食，不仅得到精神放松，也增进了小伙伴们之间的信任感与情谊一群人，在一起，走向超越，我们未来可期。/p>p> /p>p> img styledisplay: block; margin-left: auto; margin-right: auto; src/common/upload/news/2024/03/16/0950349a.jpg width500>/p> /div> /div> /div> /div> /li> /ul> /div> !-- star --> div classstar5 parallax-factor0.3>img src/ydyweb_static/picture/star5.svg>/div> /div>/div>!-- footer --> !-- footer -->footer classfooter wow fadeInUp data-wow-duration2.5s> div classw1440> div classbox> div classcode> span>img src/common/upload/universal/fragment/2024/03/16/151802jh.jpg alt微信公众号二维码 />/span> /div> div classright> div classdl> div classdd>Tel：025-83739155/div> div classdd>Fax：025-83739280/div> div classdd>Address：7th Floor, Building 6, No. 699-18, Xuanwu Avenue, Xuanwu District, Nanjing/div> /div> div classdl> div classdd>Business Cooperation：BD@delovabio.com/div> div classdd>Career Development：HR@delovabio.com/div> div classdd>Other：info@delovabio.com/div> /div> div classcopyright> Copyright 2020.Company a hrefjavascript:;>Nanjing Delova Biotech Co., Ltd. (Delova Biotech)/a> a hrefhttps://beian.miit.gov.cn/>/a> All rights reserved. /div> /div> div classto-top toTop> img src/ydyweb_static/picture/top.svg alt> /div> /div> /div>/footer>script typemodule>import(./common/assets/js/jtbc.js).then(module > { window.jtbc new module.default(); });/script>/body>/html> script src/ydyweb_static/js/swiper.min.js>/script> !-- script src/ydyweb_static/js/snowing.js>/script> --> script> // product swiper $(function() { var proudctSwiper new Swiper(.productSwiper .swiper-container, { autoplay: 5000, slidesPerView: 2, spaceBetween: 0, breakpoints: { 761: { slidesPerView: 1 } } }); proudctSwiper.container0.onmouseover function() { proudctSwiper.stopAutoplay(); } proudctSwiper.container0.onmouseout function() { proudctSwiper.startAutoplay(); } }) // anchor show $(function() { var anchors $(.homeAnchor) var oldScrollTop Wesen.getScrollTop() var logic function() { Wesen.debounce(function() { var limitScrollTop Wesen.getOffSetY.call($(#homeConcept)) - Wesen.getSpace() var nowScrollTop Wesen.getScrollTop() if(nowScrollTop oldScrollTop && nowScrollTop > limitScrollTop ) { Wesen.addClass.call(anchors, show) } else { Wesen.removeClass.call(anchors, show) } oldScrollTop nowScrollTop }, true, 1000)() } $(window).on(scroll, function() { logic() }) }) // anchor scroll to $(function() { var anchors $(.homeAnchor) anchors.find(a).on(click, function(e) { e.preventDefault() var area $( + $(this).attr(href)) var scrollY Wesen.getOffSetY.call(area) - Wesen.getSpace() Wesen.scrollTo(Math.floor(scrollY)) }) }) // anchor active $(function() { var anchors $(.homeAnchor a) var logic function() { var scrollTop Wesen.getScrollTop() $.each(anchors, function(i, node) { var area $( + $(this).attr(href)) var lowerLimit Wesen.getOffSetY.call(area) - Wesen.getSpace() var ceilLimit lowerLimit + area.outerHeight() if(scrollTop > Math.floor(lowerLimit) && scrollTop ceilLimit - 2) { Wesen.addClass.call($(this), active) } else { Wesen.removeClass.call($(this), active) } }) } $(window).on(scroll, function() { Wesen.debounce(function() { logic() }, true, 1000)() }) }) /script>/body>/html>
Port 443
HTTP/1.1 200 OKServer: nginxDate: Sun, 22 Feb 2026 11:03:37 GMTContent-Type: text/html; charsetutf-8Transfer-Encoding: chunkedConnection: keep-aliveVary: Accept-EncodingCache-Control: no-cache, must-revalidateStrict-Transport-Security: max-age31536000 !DOCTYPE html>html langen>head>meta charsetUTF-8>meta http-equivX-UA-Compatible contentIEedge>meta nameviewport contentwidthdevice-width, initial-scale1.0>title>delovabio/title>meta namekeywords content />meta namedescription content />link relicon href/favicon.ico>link relstylesheet href/ydyweb_static/css/animate.css>link relstylesheet href/ydyweb_static/css/web.css>script src/ydyweb_static/js/jquery-1.11.3.min.js>/script>script src/ydyweb_static/js/wow.min.js>/script>script src/ydyweb_static/js/wesen.js>/script>script src/ydyweb_static/js/web.js>/script>meta nameformat-detection contenttelephoneno />/head>body data-genre>!-- header -->header classheader> div classw1440> !-- logo --> h1 classheader-logo> a href/> img srccommon/assets/logo.svg alt> img src/ydyweb_static/picture/logo3.svg alt> /a> /h1> !-- menu --> div classheader-menu data-toggleoffcanvas data-target#offcanvasMenu > span>/span> span>/span> /div> /div>/header>!-- offcanvasMenu -->div classmodal nav-menu idoffcanvasMenu> div classmodal-close data-toggleoffcanvas data-target#offcanvasMenu > img src/ydyweb_static/picture/close.svg alt> /div> jtbc-pitchon pitchonligenre> ul> li genre>a href./>Home/a>/li> li genreabout>a href/about/>Company Profile/a>/li> li genrepain>a href/pain/>Pain/a>/li> li genreplatform>a href/platform/>Technology Platform/a>/li> li genrepipeline>a href/pipeline/>Product Pipeline/a>/li> li genrenews>a href/news/>News/a>/li> li genrejob>a href/job/>Job Application/a>/li> li>a hrefhttps://www.delovabio.com/ classcur>CN/a>a href/>EN/a>/li> /ul>/jtbc-pitchon>/div> link relstylesheet href/ydyweb_static/css/swiper.min.css>!-- home part1 -->div classhome-part1 stylebackground-image: url(/common/upload/universal/fragment/2024/03/18/071612ab.jpg);> div classw1440> !-- txt --> div classtxt> p classwow fadeInUp data-wow-duration2.5s>Focus on the development of new drugs in the field of pain./p> p classwow fadeInUp data-wow-duration2.5s>Provide non-opioid analgesics to satisfy unmet medical needs./p> a href/about/ classmore wow fadeInUp data-wow-duration2.5s> About Us /a> /div> /div>/div>!-- home concept -->div idhomeConcept classhome-concept stylebackground-image: url( /common/upload/universal/fragment/2024/03/16/153107vz.jpg> div classw1440> div classweb-title wow fadeInUp data-wow-duration2.5s>/div> div classweb-title2 wow fadeInUp data-wow-duration2.5s>R&D Concept/div> !-- txt --> div classtxt wow fadeInUp data-wow-duration2.5s> p>The Company was established based on the unmet medical needs and driven by technological innovation. The Company focuses on the development of high-barrier innovative technology platforms such as long-acting injection technology, topical formulation transdermal technology, nano-delivery carrier technology, prodrug modification, and solubility enhancement technology for insoluble drugs. The Company puts a lot of emphasis on patent protection throughout the full life cycle of drug development./p>p> /p>p>The Company emphasizes a global market layout and maximize the value of the projects by launching clinical studies and product registration simultaneously in China and US. The sales scale of the series of products can be up to tens of billions RMB after they are on the market. The Company's product pipeline covers two application pathways, i.e., 505(b)(1) and 505(b)(2), with a total of nearly 10 new drug products. The Company has held a pre-NDA meeting with US FDA for its first project, QP001, and has reached several agreements./p> /div> !-- more --> a href/about/#aboutConcept classmore wow fadeInUp data-wow-duration2.5s> i>Learn more/i> span>img src/ydyweb_static/picture/more.svg alt>/span> /a> !-- star --> div classstar1 parallax-factor0.3>img src/ydyweb_static/picture/star1.svg>/div> /div>/div>!-- home professional -->div idhomeProfessional classhome-professional> div classw1440> div classweb-title wow fadeInUp data-wow-duration2.5s>/div> div classweb-title2 wow fadeInUp data-wow-duration2.5s>Therapeutic Areas/div> !-- box --> div classbox wow fadeInUp data-wow-duration2.5s> div classpic>img src/common/upload/index/area/2024/03/23/1145142m.jpg alt>/div> div classwords> div classtitle>Pain/div> div classtxt>Pain is a complex physiological and psy-chological activity, and is one of the com-monest clinical symptoms. It is gaining more and more attention as the 5th vital sign after blood pressure, respiration, pulse, and body temperature. In 2020, the International Association for the Study of Pain (IASP) revised the definition of pain to an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage./div> div> a href/pain/ classmore> i>Learn more/i> span>img src/ydyweb_static/picture/more.svg alt>/span> /a> /div> /div> /div> !-- star --> div classstar2 parallax-factor0.3>img src/ydyweb_static/picture/star2.svg>/div> /div>/div>!-- home products -->div idhomeProducts classhome-products> div classbox> div classw1440> div classweb-title wow fadeInUp data-wow-duration2.5s>/div> div classweb-title2 wow fadeInUp data-wow-duration2.5s>Platform/div> !-- star --> div classstar3 parallax-factor0.3>img src/ydyweb_static/picture/star3.svg>/div> /div> /div> div classproductSwiper> div classswiper-container> div classswiper-wrapper> div classswiper-slide> div classproduct-item1 stylebackground-image: url(/common/upload/index/platform/2024/03/23/131846we.jpg);> div classsub-title>XisGelspan>®/span>/div> div classtitle>Sustained-release Gel Platform/div> div classtxt>XisGelspan>®/span>technology is suitable for improving the local duration of action of short half-life drugs.../div> a href/platform/#platformProduct1 classmore> svg width19 height19 viewBox0 0 19 19 fillnone xmlnshttp://www.w3.org/2000/svg> path dM3.89795 14.9456L15.0938 3.7497 stroke#103149 stroke-width0.791667/> path dM9.44092 3.86206H15.0388V9.45999 stroke#103149 stroke-width0.791667/> /svg> /a> /div> /div>div classswiper-slide> div classproduct-item1 stylebackground-image: url(/common/upload/index/platform/2024/03/23/1318492i.jpg);> div classsub-title>ETPFspan>®/span>/div> div classtitle>Topical Skin Preparation Platform/div> div classtxt>ETPFspan>®/span>technology is suitable for im-proving the bioavailability and ease of use of topical.../div> a href/platform/#platformProduct2 classmore> svg width19 height19 viewBox0 0 19 19 fillnone xmlnshttp://www.w3.org/2000/svg> path dM3.89795 14.9456L15.0938 3.7497 stroke#103149 stroke-width0.791667/> path dM9.44092 3.86206H15.0388V9.45999 stroke#103149 stroke-width0.791667/> /svg> /a> /div> /div> /div> /div> /div>/div>!-- home data -->div idhomeData classhome-data> div classw1440> !-- intro --> div classintro> div classintro-left wow fadeInLeft data-wow-duration2.5s> div classweb-title>/div> div classweb-title2>Pipeline/div> /div> div classintro-right wow fadeInRight data-wow-duration2.5s> div classtxt> p>Delova Biotech focuses on the unmet medical needs in the field of pain in both China and U.S. The Company has laid out nearly 10 new non-opioid analgesics, which have sequen-tially entered the clinical development stage. The Company has also applied for nearly 20 key patents./p> /div> a href/pipeline/ classmore> Learn more span>img src/ydyweb_static/picture/more2.svg alt>/span> /a> /div> /div> !-- data --> div classdata> div classbox> div classdl> div classdt>Laid out nearly 10 new non-opioid analgesics/div> div classdd>span classwow fadeIn data-wow-duration2.5s>10/span>款/div> /div> div classdl> div classdt>US pre-NDA Submitted/div> div classdd>span classwow fadeIn data-wow-duration2.5s>01/span>项/div> /div> div classdl> div classdt>Domestic Clinical/div> div classdd>span classwow fadeIn data-wow-duration2.5s>01/span>项/div> /div> /div> /div> !-- star --> div classstar4 parallax-factor0.3>img src/ydyweb_static/picture/star4.svg>/div> /div>/div>div classjob-new> div classjob-newRightTop>/div> div classjob-new-right wow fadeInLeft data-wow-duration2.5s stylevisibility: visible; animation-duration: 2.5s; animation-name: fadeInLeft;> !--div classweb-title>/div>--> div classweb-title2>Career opportunities/div> div classjob-border>/div> div classjob-new-content wow fadeInRight data-wow-duration2.5s stylevisibility: visible; animation-duration: 2.5s; animation-name: fadeInRight;> p>We respect the spirit of science, encourage free exploration, focus onclinical needs, and are committed to bringing healthier, more comfortable, and hiqher-level lives to pain patients./p>p>We provide challenging, fulfilling, and fast-growing career opportunitiesand welcome like-minded partners to join!/p> /div> a href/job/ classmore job-new-more> Learn more span>img src/ydyweb_static/picture/more2.svg>/span> /a> /div> div classjob-new-container> div classjob-new-container-title>公司和你一起高速发展/div> div classjob-new-container-title2>招聘职位/div> ul> li>a href/job/#job>临床监查员CRA/a>/li>li>a href/job/#job>临床医学经理/a>/li>li>a href/job/#job>药物分析研究员/a>/li>li>a href/job/#job>药物制剂研究员/a>/li>li>a href/job/#job>医学撰写/a>/li> /ul> /div> /div> !-- modify -->!-- home new-->div idhomeNew classhome-new> div classw1440> div classhome-new-left wow fadeInLeft data-wow-duration2.5s> div classweb-title>/div> div classweb-title2>News/div> a href/news/ classmore> Learn more span>img src/ydyweb_static/picture/more2.svg>/span> /a> /div> div classhome-new-right wow fadeInRight data-wow-duration2.5s> ul> li> div classimg onclickwindow.open(https://mp.weixin.qq.com/s?__bizMzI5MDU1MDU1NQ&mid2247483886&idx1&sn7503cc5b9ad497d3d39712f87a78ec79&chksmec1f679adb68ee8ce2bf758f6a7c46692ef8e3edbf56f7fe7404db830c00fa92226cc57e371e#rd) >img src/common/upload/news/2024/03/16/1548560r.png alt>/div> div classwords> div classtitle onclickwindow.open(https://mp.weixin.qq.com/s?__bizMzI5MDU1MDU1NQ&mid2247483886&idx1&sn7503cc5b9ad497d3d39712f87a78ec79&chksmec1f679adb68ee8ce2bf758f6a7c46692ef8e3edbf56f7fe7404db830c00fa92226cc57e371e#rd) > “无痛之路”上的冲刺跑者/div> div classmemo>2022年，生物医药行业政策调整加码，疫情笼罩、资本寒冬之下行业加速洗牌重塑，部分药企传出寒气，然而正是在这样的行业重塑过程中，真正的创新才能突出重围，牵手资本助力，迎来明亮曙光。/div> /div> div classnews-info modal idoffcanvasNew9> div classmodal-close data-toggleoffcanvas data-target#offcanvasNew9> img src/ydyweb_static/picture/close2.svg alt> /div> div classtime>2023-01-20/div> div classcaption>“无痛之路”上的冲刺跑者/div> div classcontent> div classscroll scrollCss> div classedit> /div> /div> /div> /div> /li> li> div classimg data-toggleoffcanvas data-target#offcanvasNew6 data-id6>img src/common/upload/news/2024/03/16/095340o0.jpg alt>/div> div classwords> div classtitle data-toggleoffcanvas data-target#offcanvasNew6 data-id6> 南京清普生物QP001 | CDE正式受理首款长效镇痛新药NDA/div> div classmemo>北京时间2023年09月07日，南京清普生物收到国家药品监督管理局药品审评中心（CDE）关于QP001注射液新药上市申请（NDA）的受理通知书。/div> /div> div classnews-info modal idoffcanvasNew6> div classmodal-close data-toggleoffcanvas data-target#offcanvasNew6> img src/ydyweb_static/picture/close2.svg alt> /div> div classtime>2023-09-08/div> div classcaption>南京清普生物QP001 | CDE正式受理首款长效镇痛新药NDA/div> div classcontent> div classscroll scrollCss> div classedit>p> 北京时间2023年09月07日，strong>南京清普生物收到国家药品监督管理局药品审评中心（CDE）关于QP001注射液新药上市申请（NDA）的受理通知书/strong>。两个月前，南京清普生物已收到FDA关于QP001项目NDA的正式受理函，NDA号为217593。QP001有望成为国内首款中美同步获批上市的镇痛新药。/p>p> /p>p>【关于QP001】/p>p> QP001注射液是清普生物系列非阿片类镇痛新药管线的首款产品，中美双报，可用于治疗各类急性疼痛，尤其适用于术后疼痛，相比现有同类药物在镇痛强度、安全性和镇痛维持时间上均有显著优势。QP001项目基于清普自主知识产权的难溶药物增溶技术平台（SimSolsup>TM/sup>）开发。/p>p> 此前，南京清普生物已收到FDA关于QP001项目的“Application Fee Waivers”（注册费用减免）确认函。根据美国《联邦食品、药品和化妆品法案》（FD&C Act）第736(d)(1)(C)章，strong>南京清普生物可享受QP001项目NDA注册费用部分减免的优惠，成为国内极少数获得FDA“Application Fee Waivers”（注册费用减免）的生物医药公司之一/strong>。/p>p> /p>p> 本次国内NDA基于两项确证性III期临床试验，共50余家临床研究中心参与，用时9个月不到完成全部受试者入组。两项III期临床结果优异，各主要终点和次要终点均达到统计学差异，确证了QP001注射液在24h内可保持强效镇痛，镇痛强度和安全性均优于同类药物。/p>p> /p>p> QP001项目在近2年时间里接连不断地超预期攻克国内外研发和注册里程碑，完成了多项“strong>国内第一/strong>”的壮举，彰显了公司研发团队独一无二的“清普速度”和“清普质量”。/p>p>img src/common/upload/news/2024/03/16/095419xm.jpg>/p>p> /p>p>【关于术后疼痛】/p>p> 术后疼痛是临床上最常见的急性疼痛，通常持续3～7天，创伤大的胸科和关节置换术可持续数周，日间手术离院后需1-2天镇痛。根据《中国卫生健康统计年鉴》报告，2021年我国住院手术达到8103万台，2017-2022年复合增长率（CAGR）约10%，其中约92.6%患者在手术后出现疼痛，48.7%患者术后会经历中度至重度疼痛。/p>p> 目前我国仍存在术后镇痛不足的现象，strong>我国三级甲等医院有效镇痛率也仅约30%/strong>，临床缺少强效且长效的非阿片类镇痛药。术后镇痛不足可使患者处于伤害性应激状态，影响术后恢复，导致住院时间延长，引起睡眠障碍，影响心理情绪和交感神经兴奋，增加心脏负荷影响呼吸功能，使得胃肠蠕动减少和功能恢复延迟等，并有演变为慢性疼痛的风险。/p>p> strong>国内外指南共识推荐NSAIDs类药物作为术后多模式镇痛的基础用药/strong>，按时给药，并推荐使用长效NSAIDs药物（尤其是日间手术），术前即给予COX-2选择性抑制剂预防性镇痛，进而降低术后阿片类镇痛药的用量，避免阿片类药物成瘾性、呼吸抑制、恶心呕吐、便秘等一系列不良反应。/p>p> /p>p> img src/common/upload/news/2024/03/16/095419a0.jpg>/p> /div> /div> /div> /div> /li> li> div classimg data-toggleoffcanvas data-target#offcanvasNew4 data-id4>img src/common/upload/news/2024/03/16/095022ui.jpg alt>/div> div classwords> div classtitle data-toggleoffcanvas data-target#offcanvasNew4 data-id4> 秋游 | 成群结队 快乐加倍/div> div classmemo>2023年清普生物秋游小记/div> /div> div classnews-info modal idoffcanvasNew4> div classmodal-close data-toggleoffcanvas data-target#offcanvasNew4> img src/ydyweb_static/picture/close2.svg alt> /div> div classtime>2023-09-28/div> div classcaption>秋游 | 成群结队 快乐加倍/div> div classcontent> div classscroll scrollCss> div classedit>p>早秋天气晴好，微风阵阵。为了感谢大家一直以来的付出与努力，公司在9月24日和25日于安吉组织了主题为“To the beyond 走向超越”的秋游活动，让大家从繁忙的工作中得到抽离，亲近自然、舒缓心情。/p>p>strong>浙北大峡谷·心跳在云霄/strong>/p>p>在首日行程中的浙北大峡谷不仅可以体验爬山观水的乐趣，还可以在“云幻之城”高山游乐区进行自我勇气值拉满的高空项目挑战，步步惊心桥、空中自行车、悬崖秋千等多个高空项目激发了小伙伴们挑战自我的勇气，展示真我。/p>p> img styledisplay: block; margin-left: auto; margin-right: auto; src/common/upload/news/2024/03/16/095041rm.jpg width500>/p>p> /p>p> /p>p>strong>烧烤与篝火·吹动少年的心/strong>/p>p>日落时分，伴随着烧烤炉中的炭火闪烁，大家开始了2023年秋天的第一场烧烤，刷油、翻面，生疏的动作并不影响烧烤的美味，每出炉一盘肉，就被一扫而空。举杯、摆拍，当下就是最放松且自由的时刻跳动的篝火将轻松愉悦的氛围推向高潮。/p>p> /p>p> /p>p> /p>p>img styledisplay: block; margin-left: auto; margin-right: auto; src/common/upload/news/2024/03/16/095034wc.jpg width500>/p>p>strong>竹博园·森呼吸/strong>/p>p>行程中的第二日是竹博园定向活动，分成三组的小伙伴们，组内齐心协力，组外不甘示弱。/p>p> /p>p> img styledisplay: block; margin-left: auto; margin-right: auto; src/common/upload/news/2024/03/16/095034pp.jpg width500>/p>p> /p>p>此次秋游，让大家亲近自然，享受美食，不仅得到精神放松，也增进了小伙伴们之间的信任感与情谊一群人，在一起，走向超越，我们未来可期。/p>p> /p>p> img styledisplay: block; margin-left: auto; margin-right: auto; src/common/upload/news/2024/03/16/0950349a.jpg width500>/p> /div> /div> /div> /div> /li> /ul> /div> !-- star --> div classstar5 parallax-factor0.3>img src/ydyweb_static/picture/star5.svg>/div> /div>/div>!-- footer --> !-- footer -->footer classfooter wow fadeInUp data-wow-duration2.5s> div classw1440> div classbox> div classcode> span>img src/common/upload/universal/fragment/2024/03/16/151802jh.jpg alt微信公众号二维码 />/span> /div> div classright> div classdl> div classdd>Tel：025-83739155/div> div classdd>Fax：025-83739280/div> div classdd>Address：7th Floor, Building 6, No. 699-18, Xuanwu Avenue, Xuanwu District, Nanjing/div> /div> div classdl> div classdd>Business Cooperation：BD@delovabio.com/div> div classdd>Career Development：HR@delovabio.com/div> div classdd>Other：info@delovabio.com/div> /div> div classcopyright> Copyright 2020.Company a hrefjavascript:;>Nanjing Delova Biotech Co., Ltd. (Delova Biotech)/a> a hrefhttps://beian.miit.gov.cn/>/a> All rights reserved. /div> /div> div classto-top toTop> img src/ydyweb_static/picture/top.svg alt> /div> /div> /div>/footer>script typemodule>import(./common/assets/js/jtbc.js).then(module > { window.jtbc new module.default(); });/script>/body>/html> script src/ydyweb_static/js/swiper.min.js>/script> !-- script src/ydyweb_static/js/snowing.js>/script> --> script> // product swiper $(function() { var proudctSwiper new Swiper(.productSwiper .swiper-container, { autoplay: 5000, slidesPerView: 2, spaceBetween: 0, breakpoints: { 761: { slidesPerView: 1 } } }); proudctSwiper.container0.onmouseover function() { proudctSwiper.stopAutoplay(); } proudctSwiper.container0.onmouseout function() { proudctSwiper.startAutoplay(); } }) // anchor show $(function() { var anchors $(.homeAnchor) var oldScrollTop Wesen.getScrollTop() var logic function() { Wesen.debounce(function() { var limitScrollTop Wesen.getOffSetY.call($(#homeConcept)) - Wesen.getSpace() var nowScrollTop Wesen.getScrollTop() if(nowScrollTop oldScrollTop && nowScrollTop > limitScrollTop ) { Wesen.addClass.call(anchors, show) } else { Wesen.removeClass.call(anchors, show) } oldScrollTop nowScrollTop }, true, 1000)() } $(window).on(scroll, function() { logic() }) }) // anchor scroll to $(function() { var anchors $(.homeAnchor) anchors.find(a).on(click, function(e) { e.preventDefault() var area $( + $(this).attr(href)) var scrollY Wesen.getOffSetY.call(area) - Wesen.getSpace() Wesen.scrollTo(Math.floor(scrollY)) }) }) // anchor active $(function() { var anchors $(.homeAnchor a) var logic function() { var scrollTop Wesen.getScrollTop() $.each(anchors, function(i, node) { var area $( + $(this).attr(href)) var lowerLimit Wesen.getOffSetY.call(area) - Wesen.getSpace() var ceilLimit lowerLimit + area.outerHeight() if(scrollTop > Math.floor(lowerLimit) && scrollTop ceilLimit - 2) { Wesen.addClass.call($(this), active) } else { Wesen.removeClass.call($(this), active) } }) } $(window).on(scroll, function() { Wesen.debounce(function() { logic() }, true, 1000)() }) }) /script>/body>/html>
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]